Skip to main content
In stock | Immunotherapy (Investigational)

Lemzoparlimab

Oncology Type Hematologic
Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
No Image
Description

Lemzoparlimab is classified as a CD47 (Macrophage Checkpoint) Inhibitor, sourced for use within our Immunotherapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Investigational)
Oncology Type Hematologic

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3